The design of pharmacological trials for management of substance use disorders is shifting toward outcomes of successful individual-level behavior (abstinence or no heavy use). While binary success/failure analyses are common, McCann and Li (CNS Neurosci Ther 2012; 18: 414-418) introduced ''number of beyond-threshold weeks of success'' (NOBWOS) scores to avoid dichotomized outcomes. NOBWOS scoring employs an efficacy ''hurdle'' with values reflecting duration of success. Here, we evaluate NOBWOS scores rigorously. Formal analysis of mathematical structure of NOBWOS scores is followed by simulation studies spanning diverse conditions to assess operating characteristics of five linear-rank tests on NOBWOS scores. Simulations include assessment of Fisher's exact test applied to hurdle component. On average, statistical power was approximately equal for five linear-rank tests. Under none of conditions examined did Fisher's exact test exhibit greater statistical power than any of the linear-rank tests. These linear-rank tests provide good Type I and Type II error control for comparing distributions of NOBWOS scores between groups (e.g. active vs. placebo). All methods were applied to re-analyses of data from four clinical trials of differing lengths and substances of abuse. These linear-rank tests agreed across all trials in rejecting (or not) their null (equality of distributions) at 0.05.
Introduction
Currently, no official U.S. Food and Drug Administration (FDA) guidelines exist that specifically address the development of medications to treat substance use disorders; however, a recent commentary by FDA staff 1 recommends the use of responder analyses in related clinical trials. This recommendation is consonant with FDA reviewers' comments in drug approval packages. For example, in the approval package for naltrexone XR injection for alcohol use disorder, 2 the applicant's pre-defined primary efficacy endpoint (event rate of heavy drinking) was judged to be ''inadequate'' by FDA reviewers, who commented that ''the endpoint is a result of group mean analysis and does not provide information on the effects of treatment on an individual level.'' Naltrexone XR injection received regulatory approval after the FDA conducted a responder-based re-analysis of efficacy data, with treatment success defined as an absence of heavy drinking days (an absence of five or more drinks/ day for men and an absence of four or more drinks/day for women). The reviewers stated that an absence of heavy drinking is the ''optimal definition of treatment success in alcoholism trials,'' citing data on the health consequences of heavy drinking in comparison with no heavy drinking. For other substances of abuse (e.g. tobacco, cocaine and methamphetamine), data on the relative health consequences of ''heavy'' vs. ''light'' use are lacking and, therefore, 1. We explicitly recognize and define NOBWOS scores as a bivariate interval (''regional'') censoring that produces a two-component mixture data-generating process of hurdle structure. McCann and Li 9 did not recognize the presence of censoring at all.
2. We assess if any improvements in operating characteristics, especially statistical power, could be obtained by applying some alternatives to the only testing procedure advocated by McCann and Li 9 -van der Waerden testing. 3. We perform an extensive series of simulation studies and under a wide range of conditions to assess the operating characteristics of their original procedure, some alternative linear rank tests and, importantly, binary success/failure analysis. McCann and Li 9 did not assess operating characteristics at all. 4 . In contrast to McCann and Li, 9 we detail and emphasize throughout what specific hypothesis test their procedure is assessing (difference in distribution). 5 . We demonstrate that the NOBWOS method can be applied to clinical trials of clinically divergent substances (methamphetamine, alcohol and nicotine). McCann and Li 9 only examined application to methamphetamine.
Such an extensive and practitioner-oriented statistical assessment of the NOBWOS method is essential to (1) address concerns of those who are currently satisfied with application of binary success/failure analysis and thereby (2) allow substance-use disorder research to move forward through application of the statistically more powerful technique of linear-rank testing of NOBWOS scores. To further ease application by practitioners, we restrict attention to linear-rank testing, because these are a class of distribution-free testing procedures and thereby do not require that practitioners assess any assumptions regarding parametric distributions.
Methods 2.1 Conceptual model
Suppose the active-intervention period of a randomized clinical trial has duration 0 5 and this duration is partitioned into r intervals (e.g. weeks), ½0, =rÞ, ½=r, 2=rÞ,. . ., ½ðr À 1Þ=r, , with r finite. Let the threshold period constitute the last s 5 r of these intervals, ½ðr À sÞ=r, . An individual's period of success begins at time T 1 , which defines the period of time required for onset of efficacy, and ends at a time given by the sum T 1 þ T 2 , where T 2 is the duration of efficacy. Denote the joint distribution of random variables T 1 and T 2 by fðt 1 , t 2 jhÞ, parameterized by h, where the case convention is used throughout that lowercase x denotes a particular fixed instance of random variable X. T 1 is measured from the time of randomization so that fðt 1 , t 2 jhÞ has support restricted to the upper right real quadrant 0 T 1 f g[ 0 T 2 f g (as in Figure 1 ). An individual may experience multiple, discontinuous periods of success during the active-intervention period. Denote the jth such interval by
Let the I j 2 I, 8 j, be the set of all such intervals for the individual. Of interest here only is that I j that extends from prior to and through (or to the end of) the threshold period.
The NOBWOS score W is an interval censoring 10 or, more properly, a ''regional'' censoring in that each NOBWOS score defines a region of the joint distribution of T 1 and T 2 ( Figure 1 ). Denote this mapping by
where r ðT 1 =Þe AE is the ceiling operator, rounding rðT 1 =Þ up to the nearest integer. Note that a NOBWOS score W of zero results if either of two conditions obtains. The condition r À s ð Þ=r 5 T 1 signifies that success began too late, on or after start of the threshold period, while T 1 þ T 2 5 arises when success ends too early, before conclusion of the threshold period. If the threshold period is brief, a concentration of NOBWOS scores at zero can result. This is an example of a ''hurdle'' model. 11 In this case, the ''hurdle'' is that individuals must at least be successful during the threshold period. The full distribution of W can be written as follows 
Thus far, we have implicitly assumed full follow-up past into the post-intervention period. However, because pharmacotherapy trials are designed to assess if the assigned intervention causes successful behavior, some investigators may wish to limit the assessment of success to the period of potential treatment exposure (i.e. active-intervention period). Effectively, this Winsorizes the distribution of the sum T 1 þ T 2 at . That is, any value of T 1 þ T 2 beyond is mapped back to . Denote the Winsorized joint distribution as
Þ . An interesting property of is that nearly all non-zero NOBWOS scores are confined to intervals along the upper boundary of its domain, represented, for example, by the partitions of the solid and dashed diagonal line of Figure 1 , running from coordinates f0, 84g to f84, 0g and subtending the various regions for W 2 1, 2, . . . , 9 f g . (These intervals are open at top left end and closed at bottom right end so that, for instance, the point {56, 28} maps to W ¼ 2.) Two exceptions are the maximal score, W ¼ 10 in this example, which is reduced to a point f0, g and the minimum score of W ¼ 0 given by the lower left triangular region that includes the dashed line.
While the specific formulation of the joint continuous distribution differs among full follow-up and Winsorized conditions, the mass function m of the NOBWOS scores does not, due to the interval censoring r T 1 , T 2 ð Þ!W. Whether full follow-up or Winsorized, the mass assigned to any particular NOBWOS score is the result of a double integral over a planar region bounded below in the direction of T 2 by an interval along the line segment from f0, g to f, 0g (e.g. Figure 1 ). The distinction being that Winsorization concentrates mass in the direction of T 2 along the line segment from f0, g to f, 0g for W 2 1, 2, . . . , 9 f g . 9 focused on a linear-rank test, that is also our focus here. Also, we confine the analysis to linear-rank testing because distribution-free procedures do not require that practitioners assess any assumptions regarding parametric distributions.
In the two-sample case, the general form of a linear-rank statistic is
where s r i ð Þ is a rank-score function of sample rank r i of the ith individual, i 2 1, . . . , n f g , on the outcome of interest 12 across the q groups q 2 1, 2 f g ðq updates with iÞ. For instance, sample ranks could be formed from the NOBWOS scores. The v qi are regression constants. 13 For a two-sample comparison, the v qi are indicator variables for group membership (e.g. v 1i ¼ 0 and v 2i ¼ 1), so that ' w ð Þ is the sum within one of the two groups. The van der Waerden scores are obtained from the standard
Þ. For comparison, in sections 2.2.2 and 2.3, we also examine rank score functions using two contrasting ICDFs: the standard (expectation ¼ 0, variance ¼ 1) Laplace, which is more leptokurtic (''peaked'') than the normal distribution and the central Student's t on three degrees of freedom, which is more platykurtic (''fatter tailed'') than the normal distribution, where we denote the latter by t ð3Þ . We take this one step further with a beta distribution of parameters a ¼ b ¼ 1=2 which has a ''bathtub'' shape with equal modes at each end of the support. Finally, due to its widespread use, and simplicity of formulation, we also examine Wilcoxon scores that are s r i ð Þ ¼ def r i , which yield the Mann-WhitneyWilcoxon rank sum test.
14 Tests based on linear-rank statistics employed for the purpose of testing two-sample hypotheses about location may detect other differences in populations' distributions, namely differences in shape, 15 because, at least traditionally, this is what they have been designed to do. 16 However, in many settings, comparisons of efficacy or effectiveness between treatment conditions are intended to test hypotheses of location (e.g. differences in means). To illustrate, consider the following seven simulation studies (Table 1) . A random sample of 75 observations was drawn from each of two gamma distributions of common expectation (1), an asymptotic approximation of the van der Waerden test was applied, and the p-value was recorded. Gamma distributions were employed, because these are often employed to model durations and NOBWOS scores are built upon observed durations. This process was repeated 7500 times, and Type I error was estimated as the proportion of tests yielding p 5 0:05. In the second through fourth studies, variances are equal to near equal and Type I error is close to nominal ($ 5%). However, as differences between variances become larger, Type I error inflates considerably. One can perform linear-rank tests by making the (strong) assumption that the two distributions differ only with regard to location, as is often prescribed, 14 what we can call the ''shift hypothesis.'' That assumption would need to evaluated for each application of NOBWOS scores because these scores are bounded on the closed interval 0, r À s ½ and a bounded support coerces relationship between mean and variance. 17 Practically speaking, situations where the shift hypothesis holds fully (change in mean only between populations) may be the exception (Note: This is not to say that two-sample parametric tests of location do not rely on shape restrictions. A classic example is the Behrens-Fisher problem of testing for a difference in population means in the presence of unequal variances. 18 The historical distinction being, however, that parametric tests of location such as the t-test, were designed specifically to test the shift hypothesis whereas two-sample linear rank tests were designed to test for differences in distribution). 16 Traditionally, tests based on linear rank statistics were derived assuming that ranking is performed on random variables drawn from continuous distributions. 16 However, NOBWOS scores are discrete (integer-valued) and typically restricted to a narrow range of possible values because r is measured in weeks (e.g. 0 to 10). Even if finergrained units are employed (e.g. days), ties, perhaps many, occur at NOBWOS scores of zero. Here, we adopt the convention of averaging sample rank values for tied observations, which has been shown to have identical asymptotic efficiencies to the mid-rank method and randomized-ranks method for handling ties. 13 Throughout, asymptotic approximations were employed for calculating attained significance levels (p-values), which was done because these approximations would normally be used in practice in the larger samples examined here and also to keep run times manageable for the simulation studies. 19 ) were conducted to assess the operating characteristics (Type I error and Type II error) of the five linear-rank tests (van der Waerden, Laplace, t ð3Þ , beta, and Mann-Whitney-Wilcoxon) and t-test performed on sample values of NOBWOS scores, with rationale for choice of tests given in section 2.2.1. Large sample approximations were employed for all five linear-rank tests. 20 (Note: Instead, we could have employed either full-enumeration permutation testing or sampled from the permutation distribution (see pp. 14-15 in Manly). 21 However, this would have made Monte Carlo simulation run times impracticably long.) We included a t-test because, in larger samples such as those simulated here, the tail probabilities of the t distribution are robust to even strong skewness in the sampled population. 22 Also of interest is that parametric tests may not always demonstrate greater statistical power than corresponding non-parametric tests (e.g. two-sample comparisons) as mentioned in section 2.2.1; although correspondence is often imperfect because, for example, t-tests and linear-rank tests are assessing different null hypotheses (equivalence of means vs. equivalence of distributions), unless further constraints are placed on the linear-rank test. For t-testing, Welch's approximation was employed to accommodate possibly unequal variances. 23 Comparisons also include Fisher's exact testing of $, the probability of success throughout the end-of-study threshold period plus at least one contiguous additional week during the active-intervention period (i.e. minimum success or the ''hurdle'' component). Compared to this binary outcome, NOBWOS scores are based on more and narrower censoring intervals, which should enhance statistical power for two-sample tests of location if the populations primarily differ in their distributions above W ¼ 0 (i.e. the right tail). 24 We employed Fisher's exact testing (1) because the sampling variation arises from random assignment of participants to conditions 25 and (2) to allow for the fact that cell expectations for successes can be quite small. (Note: Alternatively, one could take a data-adaptive approach and apply standard chi-square testing when cell expectations are not small.) 2.2.2.2 Design of 42 simulation conditions. Simulations were designed to have realistic temporal patterns of usage of the target substance of abuse and of missing data. Pooled data were used from seven, separate NIDA-sponsored randomized clinical trials of candidate pharmacotherapies for cocaine use disorder: baclofen, 26 cabergoline, modafinil, 27 ondansetron, 28 reserpine, 29 selegiline, 30 and tiagabine. 31 We did have data available to us from clinical trials for other substances of abuse (alcohol and tobacco). For some of these, the sample size per trial was sizable; however, the quantity of trials was small, limited to one or two. In contrast, the data from the cocaine studies were drawn from seven clinical trials and thus provided us with the largest quantity of independent samplings and as such represented the greatest opportunity to have data spanning the diversity of a treatmentseeking substance use disorder population. Data for simulations were restricted to the placebo arm to employ temporal usage patterns as similar as possible to untreated (on to which simulations artificially imposed a treatment effect of known size). For each iteration of the simulation, 150 individuals were randomly selected without replacement and half (75) of these were randomly assigned to the active arm. The quantity 150 was selected because this approximates sample sizes employed in NIDA-sponsored trials of pharmacotherapies for substance use disorders (e.g., bupropion, section 2.3). The data for each individual consisted of a matrix, the first column containing the times at which urine samples were provided and the second column containing the respective cocaine urine-metabolite results (positive or negative). By protocol for all seven studies, urine results were to be obtained three times per week. Per standard practice for NIDA-sponsored clinical trials, each column was censored at the date of the last dose of the assigned agent (here placebo) taken by the individual. Columns were also administratively censored at the trial length designated for the simulation study (either 8 or 12 weeks). An effect of active treatment was artificially introduced by randomly assigning a value for time to start of success T 1 and duration of success T 2 drawn from a bivariate exponential distribution formulated from a Gaussian copula with correlation ¼ 1=2 between T 1 and T 2 . From T 1 to T 1 þ T 2 , by definition, any usage was set to zero. The use of exponential distributions assumes a temporally constant ''risk'' of initiating successful behavior and, after successful behavior has initiated, a temporally constant risk of success ending. Clearly, this is the simplest model and alternatives are possible (section 4). Simulations used an end-of-study threshold period with durations of 1, 3, and 5 weeks ( Table 2) . Mean durations to onset of efficacy E T 1 ½ were 1, 3, 5, and 7 weeks. Mean durations of success E T 2 ½ were 12 and 14 weeks. These durations were selected to be on the same scale as the active intervention period in many trials of pharmacotherapies for substance use disorders (e.g. 8 to 12 weeks). Note that T 1 and T 2 create a period of success for the individual in addition to any such periods already present in the data for the individual from a placebo arm. Six additional simulations were conducted without artificial introduction of any success in order to characterize Type I error. One-thousand iterations were run for each of the 42 simulation studies.
Examples
Example applications are provided of two-sample testing of NOBWOS scores (van der Waerden linear-rank, t ð3Þ linear-rank, Laplace linear-rank, beta linear-rank, Mann-Whitney-Wilcoxon rank sum, and Welch's approximate t-test), and Fisher's exact test of binary end-of-study success scores. Data are drawn from four contrasting randomized clinical trials of varying length and substances of abuse: bupropion for the treatment of methamphetamine use disorder, 32 the COMBINE trial for the treatment of alcohol use disorder, 33 and varenicline for the treatment of tobacco use disorder. 34, 35 The bupropion trial was 12 weeks in length, with urine assessments scheduled for three times per week. Seventy-nine individuals were randomized to bupropion and 77 were randomized to placebo. A week was considered to be a success if the individual abstained from methamphetamine use, per available urine results. The COMBINE trial was longer in duration, with a 16-week active-intervention period. A total of 1383 individuals were randomized to nine different conditions. Rather than abstinence from all drinking, a week without heavy drinking was defined as a success. 4 The original published analysis indicated that naltrexone without cognitive behavioral therapy resulted in the greatest improvement in duration of success from heavy drinking days, compared to placebo 33 ; so we restricted our analysis here to the arms for placebo and for naltrexone without cognitive behavioral therapy. Finally, data from two phase-3 varenicline trials were combined. Across the two trials, 696 participants were randomized to varenicline, 671 were randomized to bupropion, and 685 were randomized to placebo. Analyses here are limited to the varenicline and placebo arms. The active-intervention period for each trial was 12 weeks in length with carbon dioxide exhalation measured once per week.
For the bupropion trial, NOBWOS analysis examined four different end-of-study threshold periods of lengths 1, 3, 5, and 7 weeks; analysis of the COMBINE trial examined end-of-study threshold periods of lengths 1, 3, 7, and 11 weeks; and analysis of the varenicline trial examined end-of-study threshold periods of lengths 1, 3, 5, and 7 weeks. Together, these extend the work of McCann and Li 9 who examined a threshold period of one week in the bupropion study. The Research Compliance Office of Stanford University determined that the Institutional Review Board would not consider this work to involve human subjects, because identifying information was removed from all analysis datasets such that it was not possible to readily identify individual participants.
Results

Simulations
Results of the 42 Monte Carlo simulation studies are summarized in Table 2 . Of these, 36 conditions examined Type II error and six examined Type I error. See section 2.2.2.2 for details of simulation studies' design. In interpreting these results, it is important to remember that the linear-rank tests (van der Waerden, Laplace, t ð3Þ , beta, and Mann-Whitney-Wilcoxon), Welch's approximate t-test, and Fisher's exact test are each testing a different null hypothesis. The null for the linear-rank tests is equality of distributions between the two groups Note: The duration of the end-of-study threshold period was either one, three or five weeks in length. One-thousand iterations were run for each condition. The sample size for each iteration was 150 individuals, with 75 randomly assigned to placebo and 75 randomly assigned to active. Those randomly assigned to active were assigned a time until the start of a period of success T 1 . T 1 is measured from randomization and T 2 is measured from the end of T 1 . T 1 and T 2 were randomly drawn from a bivariate exponential distribution, with means for T 1 as given in the third column. Mean for T 2 was 12 weeks or 14 weeks, as indicated. Six conditions include no artificial introduction of a period of success to permit estimation of Type I error. The van der Waerden, t ð3Þ linear-rank, Laplace linear-rank, beta linear-rank, Mann-Whitney-Wilcoxon and t-tests are all performed on NOBWOS scores. ttests allowed for unequal variances (Welch's approximation). Fisher's exact test is performed on presence or absence of success during the end-ofstudy threshold period plus one contiguous week during the active-intervention period.
(as discussed in section 2.2.1); the null for the t-test is the equality of means between the two groups; and the null for Fisher's exact test is the equality of the proportion successful between the two groups. Across the various tests examined, all else equal, statistical power declines as mean time to onset of efficacy E T 1 ½ increases. A later onset of efficacy permits less time for any differences in efficacy to diverge between conditions. In contrast, a longer duration of efficacy permits more time for divergence in efficacy between conditions. As such, all else equal, statistical power increases as mean duration of efficacy E T 2 ½ increases. Statistical power is lowest when the trial is short, E T 1 ½ is long, E T 2 ½ is short, and the duration of the end-ofstudy success threshold period is long.
Averaged across all 36 conditions examined, statistical power was approximately equal for the five linear-rank tests, being slightly higher at 73% for van der Waerden, beta, and Mann-Whitney-Wilcoxon compared to Laplace at 72% and t ð3Þ at 71%. Average statistical power is lower on average for t tests (66%) and for Fisher's exact test (64%). Under none of the 36 conditions examined did Fisher's exact test exhibit greater statistical power than any of the linear-rank tests. All linear-rank tests exhibited good Type I error control, with estimated rates typically at or very near the nominal rate of 5%. In contrast, Type I error control for t tests and for Fisher's exact test tended to be conservative with achieved error rates often below nominal, especially for Fisher's exact test.
The 36 simulation studies that assessed Type II error also reveal specific conditions for which statistical power differs markedly among the five linear-rank tests. In particular, statistical power is lower for (1) the t ð3Þ and Laplace linear-rank tests compared to (2) the van der Waerden, beta and Mann-Whitney-Wilcoxon linear-rank tests when the end-of-study threshold period is short to medium in duration (1-3 weeks), the active-intervention period is short in duration (8 weeks), and mean time to onset of efficacy is medium to long in duration (5-7 weeks). Figure 2 provides the distribution of NOBWOS scores for an end-of-study threshold of 1 week, by study arm, for each of the three clinical trials. For the bupropion trial, the distribution is strongly peaked at zero with a long, thin right tail. In contrast, the distributions for COMBINE and varenicline trials are markedly bimodal. The distribution for COMBINE trials has a large secondary peak at the highest NOBWOS score. This resulted because a large number of participants in the COMBINE trial reported no heavy-drinking days-42 for placebo and 56 for naltrexone without cognitive behavioral therapy. Eleven of these 98 participants failed to complete the 16-week active intervention period and received NOBWOS scores of zero. The major peak in the distribution for the varenicline trials is at zero with a large secondary peak at the second largest NOBWOS score. Table 3 provides estimates of various distributional shape parameters by study arm for each trial. Differences in shapes of distributions between study arms appear to be mild for the COMBINE trial and strong for the bupropion trial and varenicline trials. As such, linear-rank tests are, as tests of differences in distribution, potentially more sensitive to differences between arms for the bupropion and varenicline trials (section 2.2.1). Table 4 summarizes hypothesis testing for the linear-rank tests of NOBWOS scores, Welch's approximate t-test of NOBWOS scores and Fisher's exact test of the binary success outcome. NOBWOS and binary-success outcomes' results are shown for four different values for the end-of-study threshold durations, where some thresholds are longer for the longer trial (COMBINE). Recall that the null for the linear-rank tests, t-test, and Fisher's exact test are equality of distributions, means, and proportion successful between the two groups, respectively. The five linear-rank tests are in agreement across all 12 cases examined (three trials Â four endof-study threshold durations) in rejecting (or not) their common null (equality of distributions) at attained significance levels of p 0:05. In contrast, the t-test failed to detect a difference in location between study arms at an end-of-study threshold of seven weeks for the bupropion trial and at an end-of-study threshold of one week for the COMBINE trial. Fisher's exact test detected a difference in proportions between study arms for the three lowest end-of-study thresholds for the bupropion trial and the end-of-study threshold of 1 week for the COMBINE trial but not for the end-of-study threshold of 7 weeks for the bupropion trial. Just as we saw in the simulation studies, the linear-rank tests are detecting more differences in study arms than the t-test; and this may be due, in part, to the fact that they are testing the more general null of equality of distributions, and those distributions do appear to differ in various ways (Table 3) .
Examples
Discussion
Linear-rank tests appear to be a good choice for comparing distributions of NOBWOS scores between groups (e.g. active vs. placebo). Because estimates of Type I error and Type II error are each so similar across linear-rank tests (Table 2) , any one test could be used in application to clinical trials, with Mann-Whitney-Wilcoxon perhaps being slightly preferred for its widespread availability in statistical software packages. Use of t-tests for comparing location between groups is not recommended nor is Fisher's exact test for use with the binary success (''hurdle'') outcomes due to inferior Type I error control and Type II error control. That said, some gains in statistical power may be possible for binary success outcomes through application of tests that, unlike Fisher's, do not condition on the observed marginal counts. 36 We recommend the use of linear-rank tests on NOBWOS scores over Fisher's exact test on binary hurdle scores based on the superior operating characteristics (Type I and Type II errors) of the former. This recommendation comes with the important caveat that linear-rank tests on NOBWOS scores may detect differences between groups other than differences in location (section 2.2.1 and Table 1 ), which would need to be assessed in each application.
While it may be tempting to draw conclusions about statistical power from the three example applications of section 3.2, statistical power is, of course, a probability statement, and the results from a single clinical trial only represent a single instance of the underlying generative probabilistic process. A much fuller understanding can be obtained by accumulating many observations on the same probabilistic process (in frequentist's parlance, Figure 2 . Frequency of NOBWOS scores by condition for bupropion for the treatment of methamphetamine use disorder, 32 the COMBINE trial for the treatment of alcohol use disorder, 33 and the varenicline trials for treatment of tobacco use disorder. 34, 35 Tabulations are for an end-of-study threshold duration of 1 week. Placebo condition is black bar and active condition is gray bar. CBI : cognitive behavioral intervention.
''the long run''). Results of simulation studies, especially those based on datasets from real clinical trials-as was done here-that summarize many instances of the same probabilistic process governing statistical power are much more useful in this regard than particularly individual example applications. Put another way, Table 4 summarizes results based on real data from four clinical trials under three different conditions, whereas Table 2 summarizes the results based on real data of 42,000 trials spanning 36 conditions. The greatest benefits of particular example applications are just that-as demonstration of how to apply the proposed method to data from particular clinical trials. That said, simulation studies do have limitations, often in terms of scope. A broad range of conditions were examined by the simulation studies presented here, although other conditions could be examined as well. For instance, additional work could examine bivariate distributions for simulating time to start of success T 1 and duration of success T 2 other than a bivariate exponential distribution. Perhaps, these should encompass finite mixtures of distributions, including those in which a fraction of the population never starts successful behavior (T 1 ! 1) or a fraction of the population that responds immediately with sustained efficacy, as seen in the COMBINE trial (Figure 2 ). Here, we based simulations on data obtained from clinical trials for treatment of cocaine use disorder; additionally, other substances of abuse (e.g. opioids) could be used for this purpose. Also, simulations were conducted at moderate sample sizes (75 participants per arm) so that recommendations provided at the outset of this section apply strictly to trials of moderate size. Of interest would be to examine the small-sample ( 75 participants per arm) operating characteristics of the seven test procedures of Table 2 in application to NOBWOS scores. That said, the sample size reported in Table 2 did yield a breadth of statistical power.
Testing procedures presented here do not incorporate covariates even though covariate adjustment, especially adjustment for covariates that define randomization strata, is becoming increasingly standard in the analysis of clinical trials. To that end, one may be able to apply linear-rank hypothesis tests to residuals resulting from an ordinary least-squares fit of NOBWOS scores regressed on covariates. 37 We examined a closely related set of linear-rank tests, each based on a rank score derived from a symmetric density function, but other scoring functions could be devised and examined, including those based on asymmetric densities (e.g. exponential score function). The beta family of distributions may be especially useful in this regard. The particular symmetric beta distribution that we assessed here (a ¼ b ¼ 1=2) performed well in terms of statistical power and Type I error (Table 2 ) and this family encompasses distributions that range widely in shape from symmetric to asymmetric and unimodal to bimodal. The Mann-Whitney-Wilcoxon rank sum test employs a beta distribution to construct s with a ¼ b ¼ 1, the uniform distribution. Of interest would be analyses that identify those values of a and b that optimize the asymptotic (section 2.2.1) relative efficiency of the beta distribution compared to a standard comparator, such as Fisher's exact test. Each assessment would need to assume a particular joint distribution (or family of joint distributions) for T 1 and T 2 , and is thereby beyond the scope of the present study. Of course, if the analyst is willing to make fully parametric assumptions about the joint distribution, even more powerful likelihood ratio tests become available that recognize NOBWOS scores as a censoring applied to that joint distribution (section 2.1). We deliberately focused here on a class of distributionfree testing procedures for their ease of use for practitioners.
Although the present paper has focused exclusively on applications of the NOBWOS method in clinical trials of medications to treat substance abuse disorders, the method may have utility in other indications, such as depression. In fact, the NOBWOS method may prove useful for any disease state that is amenable to a success/ failure analysis and for which a delayed onset of pharmacological action may be observed. Within the context of the limitations described above, the current findings may have broad implications.
